Randomized study of single early instillation of (2″R)‐4′‐O‐tetrahydropyranyl‐doxorubicin for a single superficial bladder carcinoma

Stopping smoking might reduce tumour recurrence in nonmuscle‐invasive bladder cancer

“…Second, all the patients received intravesical chemotherapy with doxorubicin or mitomycin-C within 24 h of the initial TUR. It was shown that the earlier the instillation after TUR, the lower the bladder recurrence rate [19,20]. Third, up to 76% of the patients had good compliance with our protocol of intravesical therapy, compared to only 23-32% in some published series [7,11].…”

Randomized controlled study of the efficacy and safety of continuous saline bladder irrigation after transurethral resection for the treatment of non‐muscle‐invasive bladder cancer

“…A sample size calculation was based on estimated 1-year recurrence-free survival probabilities of 63% for MMC and 50% for CSBI, based on earlier single-instillation studies with other agents [5,16,17]. To detect such a difference with 80% power using a two-tailed test at a 5% significance level, assuming a registration period of 4 years, a study period of 6 years, it was estimated that 113 evaluable patients were needed.…”

Should all patients receive single chemotherapeutic agent instillation after bladder tumour resection?

“…We identified eight randomized trials testing perioperative chemotherapy after TURBT [6][7][8][9][10][11][12][13]. Most of them (six) were included in a recently published meta-analysis [14].…”

“…In the two recent studies, there is no information concerning safety of epirubicin administration (Table 4) [6][7][8][9][10][11][12][13][14]. However, according to other studies where safety profiles were presented, there were adverse events in up to 22% of treated patients (Table 4).…”